Mostrar el registro sencillo del ítem
DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)
dc.contributor.author | Hidalgo Tenorio, Carmen | |
dc.contributor.author | Pasquau, Juan | |
dc.contributor.author | Vinuesa, David | |
dc.contributor.author | Ferra, Sergio | |
dc.contributor.author | Terrón, Alberto | |
dc.contributor.author | Payeras, Albertp | |
dc.contributor.author | SanJoaquin, Isabel | |
dc.contributor.author | Martinez, Onofre Juan | |
dc.contributor.author | López Ruz, Miguel Ángel | |
dc.contributor.author | Omar, Mohamed | |
dc.contributor.author | De la Torre Lima, Javier | |
dc.contributor.author | López Lirola, Ana | |
dc.contributor.author | Palomares, Jesús | |
dc.contributor.author | Blanco, José Ramón | |
dc.contributor.author | Montero, Marta | |
dc.contributor.author | García Vallecillos, Coral | |
dc.date.accessioned | 2024-04-19T06:41:19Z | |
dc.date.available | 2024-04-19T06:41:19Z | |
dc.date.issued | 2022-03 | |
dc.identifier.citation | Viruses . 2022 Mar 4;14(3):524 | es_ES |
dc.identifier.uri | https://hdl.handle.net/10481/90899 | |
dc.description.abstract | Brief: Real-world data in naïve HIV-1 patients demonstrate that dolutegravir plus lamivudine in a multiple tablet regimen is effective, safe, and satisfactory; it causes moderately increasing weight and abdominal circumference and is administrable on a test-and-treat strategy. Background: Our objectives were to determine the real-life effectiveness and safety of DT with dolutegravir (50 mg/QD) plus lamivudine (300 mg/QD) in a multiple-tablet regimen (MTR) in naïve PLHIV followed up for 48 weeks and to evaluate the compliance and satisfaction of patients. Material and methods: An open, single-arm, multicenter, non-randomized clinical trial from May 2019 through September 2020 with a 48-week follow-up. Results: The study included 88 PLHIV patients (87.5% male) with a mean age of 35.9 years; 76.1% were MSM patients. The mean baseline CD4 was 516.4 cells/uL, with a viral load (VL) of 4.49 log10, and 11.4% were in the AIDS stage. DT started within 7 days of first specialist consultation in all patients and the same day in 84.1%; 3.4% had baseline resistance mutations (K103N, V106I + E138A, and V108I); 12.5% were lost to follow-up. At week 48, 86.3% had VL < 50 cop/uL by intention-to-treat analysis and 98.7% by per-protocol (PP) analysis. Virological failure (VF) was recorded in 1.1%, with no resistance mutation. One blip was detected in 5.2% without VF. Three reported anxiety, dizziness, and cephalgia, respectively, at week 4 and one reported insomnia at week 24; none reported adverse events at week 48. The mean weight was 4 kg higher at 48 weeks (p = 0.0001) and abdominal circumference 3 cm larger at 24 weeks (p = 0.022). No forgetfulness occurred in 98.7% of patients. Patient satisfaction was 90/100 at 4, 24, and 48 weeks. Conclusion: Real-world data demonstrate that dolutegravir plus lamivudine in MTR is effective, safe, and satisfactory, moderately increasing weight and abdominal circumference and administrable on a test-and-treat strategy. | es_ES |
dc.language.iso | eng | es_ES |
dc.rights | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/ | es_ES |
dc.title | DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks) | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |
dc.identifier.doi | 10.3390/v14030524 |